The pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS

Current Cardiology Reports

Volumn 12, Issue 2, 2010, Pages 125-132

  Sammy Elmariah, ^a   Mohler III, Emile R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aortic valve; Calcification; Statin; Stenosis

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; PLACEBO; RAPAMYCIN; ROSUVASTATIN;

AORTA STENOSIS; AORTA VALVE DISEASE; BONE METABOLISM; CALCIFICATION; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG EFFICACY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; REVIEW; VALVULAR HEART DISEASE;

ANTICHOLESTEREMIC AGENTS; AORTIC VALVE; AORTIC VALVE STENOSIS; ARTERIOSCLEROSIS; CALCINOSIS; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 77953540181     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0089-6     Document Type: Review

References (50)

1. Goldbarg SH, Elmariah S, Miller MA, Fuster V: Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007, 50:1205-1213. This is an informative review of degenerative aortic valve disease pathophysiology and therapeutic options.
2. Rajamannan NM: Calcific aortic stenosis: Lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 2009, 29:162-168. This is a thorough review highlighting all experimental models of AS.
3. O'Brien KD: Pathogenesis of calcific aortic valve disease: A disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006, 26:1721-1728.
4. Stritzke J, Linsel-Nitschke P, Markus MR, et al.: Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: Results of the longitudinal population-based KORA/MONICA survey. Eur Heart J 2009, 30:2044-2053.
5. Stewart BF, Siscovick D, Lind BK, et al.: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630-634.
6. Mohler ER 3rd, Gannon F, Reynolds C, et al.: Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
7. Moura LM, Ramos SF, Zamorano JL, et al.: Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007, 49:554-561. This is the only prospective study to demonstrate beneficial effect of statins on AS progression.
8. Cowell SJ, Newby DE, Prescott RJ, et al.: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
9. Rossebø AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356. This is a large, randomized clinical trial that failed to show a benefit of statin therapy on AS progression.
10. Thom T, Haase N, Rosamond W, et al.: Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151.
11. Otto CM, Lind BK, Kitzman DW, et al.: Association of aorticvalve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341:142-147.
12. Ix JH, Shlipak MG, Katz R, et al.: Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007, 50:412-420.
13. Katz R, Wong ND, Kronmal R, et al.: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006, 113:2113-2119.
14. Owens DS, Katz R, Johnson E, et al.: Interaction of age with lipoproteins as predictors of aortic valve calcification in the multiethnic study of atherosclerosis. Arch Intern Med 2008, 168:1200-1207.
15. Rajamannan NM, Bonow RO, Rahimtoola SH: Calcific aortic stenosis: An update. Nat Clin Pract Cardiovasc Med 2007, 4:254-262.
16. Caira FC, Stock SR, Gleason TG, et al:. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006, 47:1707-1712.
17. Kaden JJ, Bickelhaupt S, Grobholz R, et al.: Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004, 13:560-566.
18. Aikawa E, Nahrendorf M, Figueiredo JL, et al.: Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 2007, 116:2841-2850. This paper discussed using a novel nearinfrared fluorescent nanoparticle to image early stages of vascular and valvular calcification.
19. Aikawa E, Aikawa M, Libby P, et al.: Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009, 119:1785-1794.
20. Meng X, Ao L, Song Y, et al.: Expression of functional toll-like receptors 2 and 4 in human aortic valve interstitial cells: Potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol 2008, 294:C29-C35.
21. Yang X, Fullerton DA, Su X, et al.: Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol 2009, 53:491-500.
22. Osman L, Chester AH, Sarathchandra P, et al.: A novel role of the sympatho-adrenergic system in regulating valve calcification. Circulation 2007, 116:I282-I287.
23. Helske S, Oksjoki R, Lindstedt KA, et al.: Complement system is activated in stenotic aortic valves. Atherosclerosis 2008, 196:190-200.
24. Liberman M, Bassi E, Martinatti MK, et al.: Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 2008, 28:463-470.
25. Miller JD, Chu Y, Brooks RM, et al.: Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008, 52:843-850.
26. Miller JD, Weiss RM, Serrano KM, et al.: Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009, 119:2693-2701.
27. Garg V, Muth AN, Ransom JF, et al.: Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270-274.
28. Nigam V, Srivastava D: Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009, 47:828-834.
29. Tkatchenko T, Moreno-Rodriguez R, Conway S, et al.: Lack of periostin leads to suppression of Notch1 signaling and calcific aortic valve disease. Physiol Genomics 2009, 39:160-168.
30. Bosse Y, Mathieu P, Pibarot P: Genomics: The next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol 2008, 51:1327-1336. This is an informative review highlighting genetic mutations that have been associated with AS.
31. Antonini-Canterin F, Hirsu M, Popescu BA, et al.: Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008, 102:738-742.
32. Mohty D, Pibarot P, Despres JP, et al.: Age-related differences in the pathogenesis of calcific aortic stenosis: The potential role of resistin. Int J Cardiol 2009 Jan 20 (Epub ahead of print).
33. Choi BG, Vilahur G, Yadegar D, et al.: The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 2006, 6:571-587.
34. Busseuil D, Shi Y, Mecteau M, et al.: Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol 2008, 154:765-773.
35. Cimmino G, Speidl WS, Ibanez B, et al.: OxLDL Induces the expression of MCP-1 in aortic valve myofibroblasts via activation of NF-kappa B-inhibitory effects of recombinant Apo AI-Milano [abstract 1043-227]. J Am Coll Cardiol 2009, 53:A415.
36. Ertas FS, Hasan T, Ozdol C, et al.: Relationship between angiotensin-converting enzyme gene polymorphism and severity of aortic valve calcification. Mayo Clin Proc 2007, 82:944-950.
37. Simolin MA, Pedersen TX, Bro S, et al.: ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovasc Disord 2009, 9:10.
38. Cote N, Pibarot P, Pepin A, et al.: Oxidized low-density lipoprotein, angiotensin II and increased waist circumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2009 Jun 12 (Epub ahead of print).
39. Corrado A, Santoro N, Cantatore FP: Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007, 74:32-38.
40. Adami S, Braga V, Guidi G, et al.: Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000, 15:599-604.
41. Montagnani A, Gonnelli S, Cepollaro C, et al.: Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 2003, 32:15-19.
42. Price PA, Faus SA, Williamson MK: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001, 21:817-824.
43. Rapoport HS, Connolly JM, Fulmer J, et al.: Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate. Biomaterials 2007, 28:690-699.
44. Elmariah S, O'Brien KD, Budoff MJ, et al.: The relationship of bisphosphonate use to the prevalence of aortic valve calcification in women. The Multi-Ethnic Study of Atherosclerosis [abstract 1001-299]. J Am Coll Cardiol 2009, 53:A461.
45. Skolnick AH, Osranek M, Formica P, Kronzon I: Osteoporosis treatment and progression of aortic stenosis. Am J Cardiol 2009, 104:122-124.
46. Poon M, Badimon JJ, Fuster V: Overcoming restenosis with sirolimus: From alphabet soup to clinical reality. Lancet 2002, 359:619-622.
47. Wessely R, Schomig A, Kastrati A: Sirolimus and Paclitaxel on polymer-based drug-eluting stents: Similar but different. J Am Coll Cardiol 2006, 47:708-714. (Pubitemid 43243089)
48. OlssonM, RosenqvistM, Nilsson J: Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Am Coll Cardiol 1994, 24:1664-1671.
49. Spargias K, Milewski K, Debinski M, et al:. Drug delivery at the aortic valve tissues of healthy domestic pigs with a Paclitaxeleluting valvuloplasty balloon. J Interv Cardiol 2009, 22:291-298.
50. Zajarias A, Cribier AG: Outcomes and safety of percutaneous aortic valve replacement. J Am Coll Cardiol 2009, 53:1829-1836. This is a recent review summarizing patient outcomes and safety with percutaneous aortic valve replacement.